WHITE PAPER:
DPYD insight is evolving – is your panel keeping up?
See how the VeriDose® DPYD Plus Panel (RUO) performed across real-world labs
In 2024, the Association for Molecular Pathology (AMP) recommended testing DPYD variants as essential for pharmacogenomic research. The VeriDose® DPYD Plus Panel (RUO) was developed in direct response, encompassing all AMP Tier 1 and Tier 2 variants, along with four additional markers of emerging population and functional relevance.
Now, the DPYD Plus Panel white paper shares results from three Beta testing labs:
- 100% concordance with previously genotyped samples
- Robust performance across saliva, buccal, and blood-derived DNA
- High extension rates across both 96- and 384-well MassARRAY® formats
- Input range down to 5 ng DNA — with no revalidation or workflow disruption
Why download the white paper now?
This isn’t a theoretical overview; it’s a data-rich report that showcases the performance of the VeriDose® DPYD Plus Panel (RUO) across three beta testing sites, giving you:
- Confidence in a panel that fully aligns with AMP Tier 1 and 2 recommendations
- A practical benchmark for evaluating assay performance across sample types and lab conditions
- Evidence to support strategic planning, investment decisions, and future-proofing your DPYD research infrastructure
Download Now
Complete the form to receive this exclusive white paper.